Status:
COMPLETED
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to seve...
Eligibility Criteria
Inclusion
- Referred for contrast enhanced MDCT
- Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
- Diagnosed as having diabetes mellitus
Exclusion
- Unstable renal function
- Unstable diabetes
- Concurrent administration of nephrotoxic drugs
- Undergoing dialysis
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00289614
Start Date
January 1 2006
End Date
April 1 2007
Last Update
January 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bracco Diagnostics, Inc.
Princeton, New Jersey, United States, 08540